Hikal Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Hikal Ltd filed with BSE on 03 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Hikal reported Q4 FY26 revenue of INR519 crores with EBITDA margin at 20.3%, while full-year FY26 revenue stood at INR1,713 crores with EBITDA margin at 12.9%. Management attributed the quarterly improvement to recovery in Pharma demand trends and a rebound in Crop Protection volumes following industry inventory correction, while noting an exceptional impairment charge of INR47 crores on a multipurpose manufacturing facility at Panoli. Management also discussed an ongoing US FDA warning letter affecting the Bangalore pharma site, which slowed shipments and production in the year, alongside continued investment in CDMO, HPAPI and Animal Health capabilities.
Numbers mentioned
Revenue: INR519 crores (Q4 FY26)
p. 3
“For the quarter, revenue stood at INR519 crores with EBITDA margins improving to 20.3% over the previous quarter.”
Sameer Hiremath, page 3 of the filed PDF · View the filing
EBITDA margin: 20.3% (Q4 FY26)
p. 3
“For the quarter, revenue stood at INR519 crores with EBITDA margins improving to 20.3% over the previous quarter.”
Sameer Hiremath, page 3 of the filed PDF · View the filing
Revenue: INR1,713 crores (FY26)
p. 3
“For FY26, revenue stood at INR1,713 crores with EBITDA margins at 12.9%.”
Sameer Hiremath, page 3 of the filed PDF · View the filing
EBITDA margin: 12.9% (FY26)
p. 3
“For FY26, revenue stood at INR1,713 crores with EBITDA margins at 12.9%.”
Sameer Hiremath, page 3 of the filed PDF · View the filing
PAT: INR14.4 crores (Q4 FY26)
p. 5
“and PAT at INR14.4 crores after providing an exceptional item of INR47 crores for an impairment of a certain part of our manufacturing plant at Panoli.”
Kuldeep Jain, page 5 of the filed PDF · View the filing
EBITDA: INR220 crores (FY26)
p. 5
“For FY 2026, reported revenue stood at INR1,713 crores with EBITDA of INR220 crores.”
Kuldeep Jain, page 5 of the filed PDF · View the filing
PBT: negative INR79.3 crores (FY26)
p. 5
“EBITDA margin stood at 12.9%, PBT stood at negative INR79.3 crores, which is after providing INR85 crores as an exceptional item for the entire year.”
Kuldeep Jain, page 5 of the filed PDF · View the filing
Capital expenditure: INR149 crores (FY26)
p. 5
“During the year, we have incurred capital expenditure of INR149 crores for debottlenecking, regulatory upgrades, and expanding CDMO capacities.”
Kuldeep Jain, page 5 of the filed PDF · View the filing
Debt-to-equity ratio: 0.56 (as on 31 March 2026)
p. 5
“We have reduced our debt-to-equity ratio from 0.59 to 0.56 as on 31 March 2026.”
Kuldeep Jain, page 5 of the filed PDF · View the filing
Pharma revenue: INR1,021 crores (FY26)
p. 5
“For FY26, Pharma business reported revenue of INR1,021 crores and EBIT of INR58 crores and EBIT margin of 5.7%.”
Manoj Mehrotra, page 5 of the filed PDF · View the filing
Pharma revenue: INR292 crores (Q4 FY26)
p. 5
“For Q4 FY '26, Pharma business reported revenue of INR292 crores, EBIT of INR35 crores and an EBIT margin of 12%.”
Manoj Mehrotra, page 5 of the filed PDF · View the filing
Pharma plant capacity utilization: nearly 80% to 85% (FY26)
p. 5
“with pharma plants at Panoli and Bangalore operating at an average capacity utilization of nearly 80% to 85%.”
Manoj Mehrotra, page 5 of the filed PDF · View the filing
Crop Protection revenue: INR692 crores (FY26)
p. 7
“For the Crop Protection business in FY '26, we reported a revenue of INR692 crores with an EBIT of INR58 crores, which was a margin of 8.4%.”
Sameer Hiremath, page 7 of the filed PDF · View the filing
Crop Protection revenue: INR228 crores (Q4 FY26)
p. 7
“For the quarter 4 ended FY '26, the revenue was INR228 crores, with EBIT margin of 17.1%, resulting into a EBIT of INR39 crores.”
Sameer Hiremath, page 7 of the filed PDF · View the filing
Total capex: INR900-odd crores (last 4 years)
p. 13
“You're right, we did invest about INR900-odd crores in the last 4 years in capex.”
Sameer Hiremath, page 13 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
DMF filings — 5 to 6 DMF filings annually
stated firmly by Manoj Mehrotra
p. 6
“We are now targeting 5 to 6 DMF filings annually compared to 2 to 3 filings historically, reflecting the expanding depth of our development capabilities and product pipeline.”
Manoj Mehrotra, page 6 of the filed PDF · View the filing
HPAPI manufacturing facility — planned HPAPI manufacturing facility in Pune · FY28
stated firmly by Manoj Mehrotra
p. 6
“Our next milestone in this journey will be the planned HPAPI manufacturing facility in Pune targeted over FY '28.”
Manoj Mehrotra, page 6 of the filed PDF · View the filing
FY27 margins — improved levels · FY27
stated conditionally by Anish Swadi
p. 8
“While improving demand visibility, higher operating leverage, ongoing business excellence initiatives and strengthening customer engagement, we do expect FY '27 margins to sustain at improved levels.”
Anish Swadi, page 8 of the filed PDF · View the filing
FY27 revenue growth — FY27
stated firmly by Sameer Hiremath
p. 14
“But we will have growth in FY '27. The guidance will be given in the next call.”
Sameer Hiremath, page 14 of the filed PDF · View the filing
Return on capital employed — 18% to 20%
stated as an aspiration by Sameer Hiremath
p. 13
“You're right, we need to get to this 18% to 20%, if not plus level.”
Sameer Hiremath, page 13 of the filed PDF · View the filing
US FDA resolution timeline — 18 to 24 months
stated as an aspiration by Sameer Hiremath
p. 14
“It takes about 18 to 24 months.”
Sameer Hiremath, page 14 of the filed PDF · View the filing
Animal Health revenue — INR500 crores plus business · next 4 to 5 years
stated firmly by Anish Swadi
p. 19
“Yes. Again, First, to confirm, yes, we're still on track with the guidance that we gave you in September to build a INR500 crores plus business in the next 4 to 5 years.”
Anish Swadi, page 19 of the filed PDF · View the filing
US FDA inspection — towards the end of this year
stated conditionally by Sameer Hiremath
p. 15
“They will come for an inspection towards the end of this year, we expect.”
Sameer Hiremath, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said solvent prices have risen sharply since March and remain elevated, with a pass-through mechanism for CDMO that has a lag effect, while own products face a competitive market for price increases.
Answered by Sameer Hiremath
Asked by Henil Bagadia: What is the impact of raw material (BTX solvent) price increases and is there a pass-through mechanism for CDMO and own products?
p. 9
“For the CDMO products, we do have a pass-through mechanism, but there's always a lag effect.”
Sameer Hiremath, page 9 of the filed PDF · View the filing
Management said China has not raised prices on agrochemicals or raw materials, with the government seemingly absorbing cost increases for local manufacturers.
Answered by Sameer Hiremath
Asked by Henil Bagadia: Is China increasing prices on agrochemical products or raw materials given environmental crackdowns?
p. 10
“China has not increased prices on the agrochemical side. We haven't seen that.”
Sameer Hiremath, page 10 of the filed PDF · View the filing
Management attributed the shortfall to slowed production following FDA warning letter remediation at the Bangalore site, though no customers were lost.
Answered by Manoj Mehrotra
Asked by Aman Vora: Why did the company fall short of the pharma growth guidance given in February?
p. 11
“But what we have seen is that because of this FDA warning letter what we have in our Bangalore site, we have been advised by our GMP consultants to pressure test the system a little more and go slow for some of the production activities.”
Manoj Mehrotra, page 11 of the filed PDF · View the filing
Management said the FDA issue depressed pharma growth and expects historical growth levels to return once the FDA matter is resolved, expected by year end.
Answered by Sameer Hiremath
Asked by Aman Vora: How should shareholders think about the flat-to-declining top line over the past 3 years and expectations for FY27?
p. 12
“Going forward, we are confident that once the FDA matter gets resolved, which we hope to get done by the end of this year, we will start seeing growth coming back to the historical FY '24, FY '23 type of levels till which program we go here.”
Sameer Hiremath, page 12 of the filed PDF · View the filing
Management said they expect resolution within the year and cited a typical timeline of 18-24 months for API companies to resolve such issues.
Answered by Sameer Hiremath
Asked by Vinod Krishna: How confident is management that the US FDA issue will be resolved this year, and how long do such issues typically take?
p. 14
“We are hoping towards that. I mean that's the whole idea. It's been a year now since the warning letter came about 9 months ago.”
Sameer Hiremath, page 14 of the filed PDF · View the filing
Management confirmed the FDA issue is mainly affecting the CDMO business while existing business remains largely intact.
Answered by Sameer Hiremath
Asked by Raghuram: How is the US FDA issue impacting CDMO growth specifically?
p. 16
“Yes, mostly the CDMO business. So, our new products, existing business is quite intact.”
Sameer Hiremath, page 16 of the filed PDF · View the filing
Management said they have not received any indication of degrowth from customers for their current portfolio.
Answered by Anish Swadi
Asked by Henil Bagadia: Are Zoetis and BI's reported degrowth trends affecting Hikal's anti-tick molecule in Animal Health?
p. 17
“No. At this point in time, we haven't received any indications from our customers about degrowth of any products that we have currently in our portfolio.”
Anish Swadi, page 17 of the filed PDF · View the filing
Management said the underperformance was not due to management capability but due to product commoditization and increased competition on older products.
Answered by Sameer Hiremath
Asked by Aman Vora: Is Hikal's underperformance versus peers in pharma CDMO due to management bandwidth or capability issues?
p. 18
“Some of our products became old and became commoditized and there was intense competition.”
Sameer Hiremath, page 18 of the filed PDF · View the filing
Risks flagged
Elevated raw material (solvent) prices due to geopolitical conflict
p. 9
“Well, the solvent prices have really shot up in the last 3 months since March.”
Sameer Hiremath, page 9 of the filed PDF · View the filing
US FDA warning letter at Bangalore site slowing production and shipments
p. 11
“but price releases and shipments have been slowed down in the last quarter and will recover in the next 2 quarters, I'd say.”
Manoj Mehrotra, page 11 of the filed PDF · View the filing
Pricing pressure persisting in Crop Protection despite volume recovery
p. 9
“But pricing pressures still remain.”
Sameer Hiremath, page 9 of the filed PDF · View the filing
Muted NCE growth in CDMO business due to unresolved FDA matter and multi-sourcing by customers
p. 16
“So, till the FDA comes out, the new NCE growth will be muted.”
Sameer Hiremath, page 16 of the filed PDF · View the filing
Near-term raw material cost pressure from geopolitical developments including the ongoing war
p. 8
“Despite some near-term raw material cost pressures arising from geopolitical developments, particularly the war, which has happened over the last 3 months, we expect customer-supported price pass-through mechanisms to partially offset some of these increases.”
Anish Swadi, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.